Article

Benzotriazole as Privileged Scaffold: A Molecular Docking Approach toward Breast Cancer Drug Discovery

Pornima Ramdas Tambe1, Rohit Jaysing Bhor1★, Mahesh Hari Kolhe1, Radhika Bansi Varade1, Shaikh Tarnnum Bhaiya1, Akanksha Sunil Tambe1★ Corresponding author

  1. 1Department of Pharmaceutical Chemistry, Pravara Rural College of Pharmacy Pravaranagar, Rahata, Ahmednagar, Maharashtra, INDIA.

CORRESPONDENCE

Rohit Jaysing Bhor

Department of Pharmaceutical Chemistry, Pravara Rural College of Pharmacy Pravaranagar, Rahata, Ahmednagar, Maharashtra, INDIA.

rohit.bhor69@gmail.com

Received: 09-12-2025; Revised: 28-01-2026; Accepted: 18-03-2026.

Volume 15, Issue 1 · pp. 159–172 · PUBLISHED 2026 · DOI: 10.5530/ajbls.20260129

View on AJBLS original site ↗

ABSTRACT

Introduction: Breast cancer remains one of the leading causes of cancer-related mortality worldwide, particularly in hormone receptor–positive subtypes driven by estrogen signaling. In the present study, a structure-based molecular docking approach was employed to evaluate benzotriazole derivatives as potential aromatase inhibitors. Materials and Methods: The crystal structure of human aromatase (PDB ID: 3EQM) was retrieved from the Protein Data Bank and prepared using standard protein optimization protocols. Results: Twelve benzotriazole derivatives (PT-1 to PT-12) were designed and subjected to ligand preparation, energy minimization, and docking analysis using the Schrodinger Glide module. All compounds complied with Lipinski’s criteria, while PT-5 exhibited one Veber violation due to high polarity. Docking scores ranged from −6.22 to −9.90 kcal/mol, indicating favorable binding interactions with the aromatase active site. Discussion: Notably, PT-5 demonstrated the strongest binding affinity (−9.90 kcal/mol), forming multiple conventional hydrogen bonds with VAL369, VAL370, PRO429, MET311, and THR310, along with hydrophobic and π–interactions. PT-4 and PT-11 exhibited balanced docking performance and favorable pharmacokinetic profiles, suggesting improved drug-likeness compared to PT-5. Interaction analysis revealed that residues VAL369, VAL370, ALA306, ALA307, LEU152, PHE430, MET303, and CYS437 play crucial roles in ligand stabilization through hydrogen bonding, π–π stacking, π–sulfur, and hydrophobic interactions. Conclusion: The conclusion was the findings highlight benzotriazole as a promising scaffold for aromatase inhibition and support further in vitro and in vivo investigations to validate its therapeutic potential in breast cancer management.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Tambe, P. R., Bhor, R. J., Kolhe, M. H., Varade, R. B., Bhaiya, S. T., & Tambe, A. S. (2026). Benzotriazole as Privileged Scaffold: A Molecular Docking Approach toward Breast Cancer Drug Discovery. Asian Journal of Biological and Life sciences, 15(1), 159–172. https://doi.org/10.5530/ajbls.20260129